Ureas and their use in the treatment of heart failure

1. A compound of the following formula and/or a pharmaceutically acceptable salt thereof

wherein

n is one, two, or three;

R 1 is optionally substituted 2-oxo-imidazolidin-1-yl;

R 2 is optionally substituted aryl, optionally substituted aralkyl; optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl or optionally substituted heterocycloalkyl;

R 3 is hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl;

R 4 is hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl;

R 5 is hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl;

each R 6 and R 7 is independently selected from hydrogen, aminocarbonyl, alkoxycarbonyl, optionally substituted alkyl, and optionally substituted alkoxy, or R 6 and R 7 , taken together with the carbon to which they are attached, form an optionally substituted 3- to 7-membered ring which optionally incorporates one or two additional heteroatoms, selected from N, O, and S in the ring; and

R 13 is hydrogen, halo, cyano, hydroxyl, optionally substituted alkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl.

2. A compound of claim 1 and/or a pharmaceutically acceptable salt thereof, wherein R 2 is optionally substituted phenyl, optionally substituted naphthyl, optionally substituted pyrrolyl, optionally substituted thiazolyl, optionally substituted isooxazolyl, optionally substituted pyrazolyl, optionally substituted oxazolyl, optionally substituted 1,3,4-oxadiazolyl, optionally substituted pyridinyl, optionally substituted pyrazinyl, optionally substituted pyrimidinyl, or optionally substituted pyridazinyl.

3. A compound of claim 1 and/or a pharmaceutically acceptable salt thereof, wherein R 2 is pyridin-3-yl, pyridin-4-yl, pyridin-1-oxide, phenyl, pyrimidin-5-yl, or isoxazol-3-yl, wherein each of the pyridin-3-yl, pyridin-4-yl, pyridin-1-oxide, phenyl, pyrimidin-5-yl, and isoxazol-3-yl is optionally substituted with lower alkyl, lower alkoxy, halo, cyano or acetyl.

4. A compound of claim 3 and/or a pharmaceutically acceptable salt thereof, wherein R 2 is pyridin-3-yl which is optionally substituted with lower alkyl; R 2 is pyridin-4-yl which is optionally substituted with lower alkyl; phenyl which is optionally substituted with halo; optionally substituted pyrimidin-5-yl; or optionally substituted isoxazol-3-yl.

5. A compound of claim 1 and/or a pharmaceutically acceptable salt thereof, wherein the compound is chosen from compounds of the following formula

wherein

T 2 is —C═or —N═; and

R 16 is selected from hydrogen, halo, cyano, optionally substituted alkyl, and optionally substituted alkoxy.

6. A compound of claim 5 and/or a pharmaceutically acceptable salt thereof, wherein T 2 is —C═.

7. A compound of claim 5 and/or a pharmaceutically acceptable salt thereof, wherein T 2 is —N═.

8. A compound of claim 5 and/or a pharmaceutically acceptable salt thereof, wherein R 16 is selected from hydrogen, methyl, fluoro, cyano, methoxy, and acetyl.

9. A compound of claim 8 , and/or a pharmaceutically acceptable salt thereof, wherein R 16 is hydrogen or methyl.

10. A compound of claim 1 and/or a pharmaceutically acceptable salt thereof, wherein R 3 is hydrogen, cyano, fluoro, chloro, or methyl.

11. A compound of claim 10 and/or a pharmaceutically acceptable salt thereof, wherein R 3 is hydrogen or fluoro.

12. A compound of claim 1 and/or a pharmaceutically acceptable salt thereof, wherein each R 4 and R 5 is independently selected from hydrogen, pyridinyl, halo and optionally substituted lower alkyl.

13. A compound of claim 12 and/or a pharmaceutically acceptable salt thereof, wherein R 4 is hydrogen, pyridinyl, trifluoromethyl, or fluoro.

14. A compound of claim 12 and/or a pharmaceutically acceptable salt thereof, wherein R 5 is hydrogen, chloro, fluoro, methyl, or trifluoromethyl.

15. A compound of claim 1 and/or a pharmaceutically acceptable salt thereof, wherein R 13 is hydrogen, halo, hydroxyl, or lower alkyl.

16. A compound of claim 15 and/or a pharmaceutically acceptable salt thereof, wherein R 13 is hydrogen or fluoro.

17. A compound of claim 1 and/or a pharmaceutically acceptable salt thereof, wherein n is one.

18. A compound of claim 1 and/or a pharmaceutically acceptable salt thereof, wherein n is two.

19. A compound of claim 1 and/or a pharmaceutically acceptable salt thereof, wherein n is three.

20. A compound of claim 1 and/or a pharmaceutically acceptable salt thereof, wherein each R 6 and R 7 is independently selected from hydrogen and methyl.

21. A compound of claim 1 and/or a pharmaceutically acceptable salt thereof, wherein R 6 and R 7 are hydrogen.

22. A compound of claim 17 and/or a pharmaceutically acceptable salt thereof, wherein R 6 is methyl and R 7 is hydrogen.

23. A compound of claim 1 and/or a pharmaceutically acceptable salt thereof, wherein R 3 , R 4 , R 5 , and R 13 are hydrogen.

24. A compound of claim 1 and/or a pharmaceutically acceptable salt thereof, wherein one of R 3 , R 4 , R 5 , and R 13 is halo, methyl or cyano and the others are hydrogen.

25. A compound of claim 1 and/or a pharmaceutically acceptable salt thereof, wherein two of R 3 , R 4 , R 5 , and R 13 are independently halo or cyano and the others are hydrogen.

26. A compound of claim 1 and/or a pharmaceutically acceptable salt thereof, wherein

R 2 is pyridin-3-yl which is optionally substituted with lower alkyl; phenyl which is optionally substituted with halo; optionally substituted pyrimidin-5-yl; or optionally substituted isoxazol-3-yl;

R 3 is hydrogen or fluoro;

R 4 is hydrogen, pyridinyl or fluoro;

R 5 is hydrogen or fluoro;

each R 6 and R 7 is independently selected from hydrogen and methyl; and

R 13 is hydrogen or fluoro.

27. A compound of claim 1 and/or a pharmaceutically acceptable salt thereof, wherein

R 2 is pyridin-3-yl which is optionally substituted with lower alkyl; phenyl which is optionally substituted with halo; optionally substituted pyrimidin-5-yl; or optionally substituted isoxazol-3-yl;

R 3 is hydrogen or fluoro;

R 4 is hydrogen, pyridinyl or fluoro;

R 5 is hydrogen or fluoro;

each R 6 and R 7 is independently selected from hydrogen and methyl; and

R 13 is hydrogen or fluoro,

wherein one of R 3 , R 4 , and R 5 is not hydrogen.

28. A compound of claim 1 and/or a pharmaceutically acceptable salt thereof, wherein the compound is selected from

N-{5-fluoro-3-[(3-methyl-2-oxoimidazolidinyl)methyl]phenyl}(3-pyridylamino)carboxamide; and

N-{5-fluoro-3-[(3-methyl-2-oxoimidazolidinyl)methyl]phenyl}[(6-methyl(3-pyridyl))amino]carboxamide.

29. A pharmaceutical composition comprising a pharmaceutically acceptable excipient, carrier or adjuvant and a compound of claim 1 and/or a pharmaceutically acceptable salt thereof.

30. A pharmaceutical composition of claim 29 , wherein the composition is formulated in a form chosen from injectable fluids, aerosols, tablets, pills, capsules, syrups, creams, gels, and transdermal patches.

31. A packaged pharmaceutical composition, comprising a pharmaceutical composition of claim 29 and instructions for using the composition to treat a patient suffering from a heart disease.

32. The packaged pharmaceutical composition of claim 31 wherein the heart disease is heart failure.